Galera Therapeutics (NASDAQ: GRTX) stock is up 22% premarket this morning. GRTX stock is up on the announcement that there is to be a meeting with the FDA. The FDA is, as with all development pharma activity, the one true and important decision maker. If they say yes to a treatment then it’s worth a lot of money. If they say no then it’s worth nothing and all the cash spent to develop it has been wasted. So, meetings with the FDA are important.
The problem is that there’s already been that ruling from the FDA on Galera Therapeutics: Galera Therapeutics (NASDAQ: GRTX) stock imploded 80% and change. GRTX stock plunged because the Food and Drug Administration, the FDA, refused authorisation for the company’s treatment for radiation caused mouth ulcers in cancer patients. There is a speculative opportunity here as a result. But it is indeed highly, highly speculative and is something that most won’t even want to consider.
The FDA’s decision: “Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced that it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the Company’s New Drug Application (NDA) for avasopasem manganese (avasopasem) for radiotherapy-induced severe oral mucositis (SOM) in patients with head and neck cancer undergoing standard-of-care treatment. In the CRL, the FDA communicated that the results from the Phase 3 ROMAN trial together with the supporting data from the GT-201 trial are not sufficiently persuasive to establish substantial evidence of avasopasem’s effectiveness and safety for reducing severe oral mucositis in patients with head and neck cancer. FDA stated that results from an additional clinical trial will be required for resubmission.”
Galera Therapeutics stock price from Google Finance
As we can see the Galera stock price did not recover from that blow - indeed it’s continued to drift lower.
Today’s news: “announced that a Type A Meeting has been scheduled for September 28, 2023 with the U.S. Food and Drug Administration (FDA) regarding the Complete Response Letter (CRL) received for the Company’s New Drug Application (NDA) for avasopasem manganese (avasopasem). The FDA is expected to issue written meeting minutes approximately 30 days following the meeting. "We look forward to further understanding the FDA’s review of our NDA for avasopasem and the data from our two randomized placebo-controlled clinical trials,” said Mel Sorensen, M.D., Galera’s President and CEO.”
This is not a meeting to discuss a reconsideration of the FDA’s decision. It’s one to discover the finer details of why the decision was as it was. We’re not going to see the FDA declare “Ooops, you’re right, we’ll approve it right away” as a result of this meeting.
We think a 20% price rise in Galera on the back of this meeting being scheduled is very, very, hopeful indeed.